

Sesquiterpenes from *Baekkea frutescens*

Wing-Yan Tsui and Geoffrey D. Brown*


Chemistry Department, The University of Hong Kong, Pokfulam Road, Hong Kong

Received April 29, 1996[⊗]

The aerial parts of *Baekkea frutescens* yielded three sesquiterpenes (**1–3**) belonging to the humulane, caryophyllane, and clovane classes, including the new sesquiterpene (–)-clovane-2,9-diol (**3**). Circumstantial evidence is presented that these classes are biogenetically related.

Baekkea frutescens L. (syn. *Baekkea chinensis* Gaertner; Myrtaceae) is widespread in Hong Kong and is used in traditional Chinese medicine for treating rheumatism and snake bites.¹ There has been one previous phytochemical study of *B. frutescens*, which reported three phloroglucinols.²

Column chromatography followed by HPLC of a CH₂Cl₂ extract of the aerial parts of *B. frutescens* yielded three sesquiterpenes (**1–3**), which were identified largely on the basis of 2D-NMR spectroscopy. Analysis of the results of the PFG-HSQC, the PFG-HMBC, and the ¹H–¹H COSY (proton–proton couplings) NMR spectra (500 MHz) established the structure of **1** and also allowed determination of chemical shifts for all carbons and protons in the molecule. Compound **1** has been isolated previously as a constituent of *Zingiber zerumbet* and named humulene epoxide II;^{3–6} our spectra agreed well with ¹³C- and partial ¹H-NMR data reported for humulene epoxide II in the literature.^{3,7,8} Full ¹³C- and ¹H-NMR assignments for **1** are presented in Table 1 for the first time. The optical rotation of humulene epoxide II from nature is variously reported as –25°, –31°, –10° and –43°,^{4,5,8,9} whereas **1** from *Baekkea frutescens* had zero optical rotation and must therefore be a racemic mixture of *trans* epoxides.



The ¹³C-NMR signals (125 MHz) for the C-12- and C-13 methyl groups in **1** showed strong line broadening relative to other peaks. This broadening was progressively reduced as the temperature was raised, both resonances attaining a normal line-shape at 60 °C in C₆H₆-d₆. Such behavior would be consistent with a degree of conformational rigidity in the portion of the 11-membered ring next to the *gem*-dimethyl group, relative to the rest of the molecule, which is overcome at higher temperatures. In support of this, correlations in the NOESY spectrum clearly demonstrated that there is a preferred conformation for the two double bonds flanking the C-12 and C-13 methyl groups (as shown in Scheme 1) at room temperature (NOESY gave no clear indication of a conformational preference for the other half of the ring). Observation of this conforma-

tional preference is interesting because the two double bonds are almost parallel, and the alkene protons at the C-2 and C-10 positions project towards different faces of the molecule. This same conformation has been proposed to account for rearrangements of humulene epoxide II (**1**) in superacid and has been suggested to be the most stable conformer from molecular modeling studies.¹⁰ Our own molecular modeling calculations (using the MM2* force field of MacroModel¹¹) failed to show a clear conformational preference for **1**: the minimized energies for the five lowest energy conformers were within 10 kJ mol^{–1} of each other. Conformations calculated for the second and third lowest energy states incorporated the partial structures shown for conformers **a** and **b** in Scheme 1.

The observed conformation for **1** would naturally yield *trans*-caryophyllanes (possibly via an intramolecular ene reaction), which are often found in association with humulanes. In support of this possibility, we have isolated two other sesquiterpenes (**2** and **3**) from the same extract whose structures are consistent with such cyclization of (±)-humulene epoxide II.

Compound **2** was identified as the known compound caryophyllene-4β,5α-epoxide (1*R*,4*R*,5*R*,9*S*) from its NMR spectra (300 MHz) and optical rotation.^{12–16} Our assignments of the proton and carbon resonances for **2** agreed with those reported in the literature.¹⁷ Compound **2** can clearly be formed from **1** by direct cyclization of the 6*R*,7*R* form of **1**, as postulated above (Scheme 2).

Compound **3** was identified as the novel compound (–)-clovane-2,9-diol (1*R*,2*R*,5*R*,8*S*,9*S*) in the following manner. Accurate mass spectrometry of **3** demonstrated the molecular formula C₁₅H₂₆O₂. IR spectroscopy showed a strong band at 3383 cm^{–1} indicative of hydroxyl group functionality(ies). The ¹³C/DEPT-NMR spectrum (125 MHz) indicated 15 carbons with 24 directly attached protons and analysis of the chemical shifts suggested the presence of two oxygenated carbons (δ_C 80.9 CH, 75.1 CH) and the absence of double bonds. Consequently, **3** was established as a tricyclic compound with two hydroxyl groups. The complete structure for **3** and assignments for all proton and carbon resonances were deduced from analysis of 2D-NMR spectra (500 MHz) (high-resolution spectra were required because of the overlap of several proton chemical shifts), and the relative stereochemistry of **3** was deduced from correlations observed in the NOESY spectrum (Table 2). In fact, both the ¹H- and ¹³C-NMR spectra for **3** agreed well with those reported for clovane-2,9-diol (1*S*,2*S*,5*S*,8*R*,9*R*).^{12,13,18} The optical rotation for **3** from *B. frutescens* ([α]_D –3.5°) was of opposite sign to that

[⊗] Abstract published in *Advance ACS Abstracts*, October 15, 1996.

Table 1. NMR Data for Compound **1**


position	δ_C	multiplicity ^a	δ_H	HMBC correlation from δ_H to δ_C	¹ H- ¹ H COSY correlation (δ)
1	40.2	CH ₂	1.99 1.87	131.9, 125.7, 36.5, 29.0 131.9, 125.7	4.99, 1.87 4.99, 1.99
2	125.7	CH	4.99	36.6, 15.1	1.99, 1.87
3	131.9	C			
4	36.6	CH ₂	2.20 2.10	131.9, 125.7, 24.8 131.9, 125.7, 24.8	2.10, 2.14 2.20
5	24.8	CH ₂	2.14 1.37	62.0 63.2, 36.6	2.20, 1.37 2.52, 2.14
6	62.0	CH	2.52	24.8	1.37
7	63.2	C			
8	42.5	CH ₂	2.57 1.65	143.1, 122.1, 63.2, 17.2 143.1, 122.1, 63.2, 17.2	5.29, 1.65 5.92, 2.57
9	122.1	CH	5.29	143.1, 63.2, 42.6, 36.5	5.16, 2.57, 1.65
10	143.1	CH	5.16	122.1, 42.6, 36.5, 29.0, 25.6	5.29
11	36.5	C			
12	29.0	CH ₃	1.09	143.1, 40.2, 36.5, 25.6	
13	25.6	CH ₃	1.11	143.1, 40.2, 36.5, 29.0	
14	17.2	CH ₃	1.31	63.2, 42.6	
15	15.1	CH ₃	1.57	131.9, 125.7, 36.6	

^a Values were determined from the DEPT spectrum.

Table 2. NMR Data for Compound **3**


position	δ_C	multiplicity ^a	δ_H	HMBC correlation from δ_H to δ_C	¹ H- ¹ H COSY correlation (δ)	NOESY correlation (δ)
1	44.2	C				
2	80.9	CH	3.79	47.6, 35.5, 26.4	1.72, 1.51	1.72, 1.56, 1.51, 0.91, 0.86
3	47.6	CH ₂	1.72 1.51	80.9, 50.5, 44.2, 37.2, 25.4 80.9, 44.2, 37.2, 31.5, 25.4	3.79, 1.51 3.79, 1.72	3.79, 1.51, 0.86 3.79, 1.72, 1.03
4	37.2	C				
5	50.5	CH	1.43	44.2, 37.2, 35.5, 31.5, 26.4, 25.4, 20.7		2.00, 1.03
6	20.7	CH ₂	1.42 1.32	50.5, 34.7, 33.1 50.5, 37.2, 33.1	1.32, 1.12 1.42, 1.39, 1.12	1.12 0.86
7	33.1	CH ₂	1.39 1.12	75.1, 50.5, 34.7, 28.3, 20.7 75.1, 34.7, 28.3, 20.7	1.32, 1.12 1.42, 1.39, 1.32	0.96 3.33, 1.42
8	34.7	C				
9	75.1	CH	3.33	35.5, 26.4	2.00, 1.64	2.00, 1.64, 1.12, 0.96
10	26.0	CH ₂	2.00 1.64	26.4 75.1, 44.2, 34.7	3.33, 1.68, 1.64, 1.08 3.33, 2.00, 1.68, 1.08	3.33, 1.64, 1.43 3.33, 2.00
11	26.4	CH ₂	1.68 1.08	50.5, 44.2, 35.5, 26.0 35.5	2.00, 1.64, 1.08 2.00, 1.68, 1.64	1.08 1.68
12	35.5	CH ₂	1.56 0.91	75.1, 50.5, 44.2, 34.7, 33.1, 28.3, 26.4 80.9, 75.1, 44.2, 34.7, 28.3, 26.4	0.91 1.56	3.79, 0.91 3.79, 1.56
13	25.4	CH ₃	0.86	50.5, 47.6, 37.2, 31.5		3.79, 1.72, 1.32, 1.03
14	31.5	CH ₃	1.03	50.5, 47.6, 37.2, 25.4		1.51, 1.43, 0.86
15	28.3	CH ₃	0.96	75.1, 35.5, 34.7, 33.1		3.33, 1.39

^a Values were determined from the DEPT spectrum.

Scheme 1. Preferred Conformations for **1** (a and/or b) As Deduced from NOESY Correlations (Indicated by Double-Headed Arrows)

reported in the literature (variously given as $+3.2^\circ$ or $+5^\circ$ from both natural and synthetic sources,^{13,19} (+)-clovane-2,9-diol (1*S*,2*S*,5*S*,8*R*,9*R*) prepared by ourselves from **2** (commercially available) according to a literature procedure¹⁹ gave $[\alpha]_D +3.8^\circ$ (*c* 4.5, CHCl₃). It thus seems likely that **3** is the mirror image of the compound reported in the literature: we propose the name (-)-clovane-2,9-diol, associated with the absolute stereochemistry (1*R*,2*R*,5*R*,8*S*,9*S*).

Compound **3** can be derived from the 6*S*,7*S* form of **1** by cyclization to caryophyllene oxide

Scheme 2. Proposed Conversion of **1** (Racemic) into **2** and **3**

(1*S*,4*S*,5*S*,9*R*) followed by subsequent rearrangement to the clovane skeleton (Scheme 2). (+)-Clovane-2,9-diol (1*S*,2*S*,5*S*,8*R*,9*R*) has been reported to arise from **2** both naturally and synthetically by just such a rearrangement.^{13, 19}

Experimental Section

General Experimental Procedures. FTIR spectra were recorded in CCl₄ on a Shimadzu FTIR-8201 PC

instrument. All NMR experiments were performed on a Bruker DPX 300 or a DRX 500 instrument with CDCl₃ as solvent. PFG-HSQC and PFG-HMBC spectra were normally recorded with 2048 data points in F₂ and 128 data points in F₁, while high-resolution experiments had 8192 data points in F₂ and 1024 data points in F₁. MS were recorded in EI mode (70 eV) on a Finnigan-MAT 95 MS spectrometer. Column chromatography was made on Si gel Merck (60–200 μm). TLC plates were developed using *p*-anisaldehyde. HPLC separations were performed using a PREP-SIL 20 mm × 25 cm column, flow rate 8 mL/min, with refractive index detection.

Plant Material. *Baekkea frutescens* was collected in November 1995, during flowering at Plover Cove Country Park, New Territories, Hong Kong. A voucher specimen is deposited in the University of Hong Kong Herbarium (GDBROWN 96/1).

Extraction and Isolation. The aerial parts of *B. frutescens* (577 g) were ground to a fine powder under liquid N₂ and immediately extracted with CH₂Cl₂ in a Soxhlet apparatus (8 h). The organic extract was then dried and evaporated under vacuum to yield a dark green oil (8.85 g; 1.5% w/w), which was separated chromatographically as follows: **1** (15 mg) by column chromatography (*R_f* 0.25 in 6% EtOAc/hexane; staining violet) followed by HPLC (*t_R* 15.9 min in 6% EtOAc/hexane); **2** (15 mg) by column chromatography (*R_f* 0.25 in 6% EtOAc/hexane; staining yellow) followed by HPLC (*t_R* 16.4 min in 6% EtOAc/hexane); **3** (7 mg) by column chromatography (*R_f* 0.12 in 50% EtOAc/hexane; staining pink) followed by HPLC (*t_R* 23.9 min in 50% EtOAc/hexane).

(±)-Humulene epoxide II (1): obtained as a colorless oil; [α]_D 0.0° (*c* 0.64, CHCl₃,); IR ν max 2961, 2930, 2870, 1690, 1460, 1448, 1387, 1074 cm⁻¹; ¹H NMR (500 MHz) δ 5.29 (1H, ddd, *J* = 15.8, 10.2, 5.1 Hz, H-9), 5.16 (1H, d, *J* = 15.8 Hz, H-10), 4.99 (1H, dd, *J* = 9.5, 5.2 Hz, H-2), 2.57 (1H, dd, *J* = 12.2, 5.1 Hz, H-8), 2.52 (1H, dd, *J* = 10.2, 3.9 Hz, H-6), 1.99 (1H, dd, *J* = 13.7, 9.2 Hz, H-1), 1.87 (1H, dd, *J* = 13.7, 5.2 Hz, H-1), 1.65 (1H, dd, *J* = 12.2, 10.2 Hz, H-8), 1.57 (3H, s, H-15), 1.31 (3H, s, H-14), 1.11 (3H, s, H-13); ¹³C-NMR data, see Table 1; EIMS *m/z* [M⁺] 220.1822 (Δ +0.5 mmu for C₁₅H₂₄O) (2), 138 (36), 133 (30), 111 (30), 109 (100), 107 (57).

Caryophyllene 4β,5α-Epoxyde (2). Data were in agreement with published values.^{12–18}

(-)-Clovane-2,9-diol (3): obtained as a white solid; mp 147–149 °C; [α]_D -3.5° (*c* 0.16, CHCl₃); IR ν max 3383, 2952, 2930, 2868, 1463, 1074 cm⁻¹; ¹H NMR (500 MHz) δ 3.79 (1H, dd, *J* = 10.0, 6.0 Hz, H-2), 3.33 (1H, s, H-9), 1.03 (3H, d, *J* = 2.0 Hz, H-14), 0.96 (3H, s, H-15), 0.86 (3H, s, H-13); ¹³C-NMR data, see Table 2; EIMS *m/z* [M⁺] 238.1929 (Δ +0.3 mmu for C₁₅H₂₆O₂) (25), 220 (57), 182 (49), 179 (42), 164 (100), 161 (32), 123 (18).

Acknowledgment. We would like to thank Mr. Wong Man-Kin of the Chemistry Department for help with the molecular modeling studies; Drs. Richard Cortlett and Richard Saunders of the Department of Ecology and Biodiversity, University of Hong Kong, for help in identification of the plant material; and the University of Hong Kong for provision of a postgraduate studentship to W.-Y. T.

References and Notes

- Cheung, S. C.; Li, N. H. *Chinese Medicinal Herbs of Hong Kong. Vol. 1*; Commercial Press: Hong Kong, 1991; p 96.
- Fujimoto, Y.; Usui, S.; Makino, M.; Sumatra, M. *Phytochemistry* **1996**, *41*, 923–925.
- Damodaran, N. P.; Dev, S. *Tetrahedron* **1968**, *24*, 4123–4132.
- Damodaran, N. P.; Dev, S. *Tetrahedron* **1968**, *24*, 4133–4142.
- Damodaran, N. P.; Dev, S. *Tetrahedron* **1968**, *24*, 4113–4122.
- Gupta, A. S.; Dev, S. *Tetrahedron* **1971**, *27*, 635–644.
- Schneider, H.-J.; Agrawal, P. K. *Magn. Reson. Chem.* **1986**, *24*, 718–722.
- Itokawa, H.; Yoshimoto, S.; Morita, H. *Phytochemistry* **1988**, *27*, 435–438.
- Ramaswami, S. K.; Bhattacharyya, S. C. *Tetrahedron* **1962**, *18*, 575–579.
- Gatilova, V. P.; Korchagina, D. V.; Gatilov, Y. V.; Bagryanskaya, I. Y.; Barkhash, V. A. *Zh. Org. Khim.* **1991**, *27*, 2301–2318.
- Mohamadi, F.; Richards, N. G.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. *J. Comput. Chem.* **1990**, *11*, 440–467.
- Nisnevich, G. A.; Korchagina, D. V.; Makal'skii, V. I.; Dubovenko, Z. V.; Barkhash, V. A. *Zh. Org. Khim.* **1993**, *29*, 524–541.
- Heymann, H.; Tezuka, Y.; Kikuchi, T.; Supriyatna, S. *Chem. Pharm. Bull.* **1994**, *42*, 138–146.
- Barrero, A. F.; Molina, J.; Oltra, J. E.; Altarejos, J.; Barragan, A.; Lara, A.; Segura, M. *Tetrahedron* **1995**, *51*, 3813–3822.
- Giersch, W. K.; Boschung, A. F.; Snowden, R. L.; Schulte-Elte, K.-H. *Helv. Chim. Acta* **1994**, *77*, 36–40.
- Orihara, Y.; Saiki, K.; Furuya, T. *Phytochemistry* **1994**, *35*, 635–639.
- Krebs, H. C.; Rakotoarimanga, J. V.; Habermehl, G. G. *Magn. Reson. Chem.* **1990**, *28*, 124–128.
- Delgado, G.; Cardenas, H.; Pelaez, G.; Romo de Vivar, A. *J. Nat. Prod.* **1984**, *47*, 1042–1045.
- Aebi, A.; Barton, D. H. R.; Lindsey, A. S. *J. Chem. Soc.* **1953**, 3122–3129.

NP960419W